Arcellx Signs a Development Evaluation and License Agreement with Pfenex for Advancing SparX Proteins

Shots:

• Pfenex to receive R&D funding along with $2.6M up to $18M as development, regulatory & commercial milestones and royalties on WW sales of products. Arcellx to get access to Pfenex expression technology platform to advance sparX proteins, activating, silencing & reprograming antigen- receptor complex T-cell based therapies
• Arcellx’s first sparX protein has completed its process development program leading to the initiation of the second sparX program, both focusing on hematologic malignancies
• The Pfenex expression technology platform is protein expression technology based on Pseudomonas fluorescens used to develop therapeutically equivalent vaccines, biologics and biosimilars which includes CRM197, PF708, PF743 & PF745

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Pfenex